Singapore at a glance
- Population
- 6.1 million 2025
- Life expectancy at birth
- 83.3 years, 2024
- People aged 65 and over
- 14.2 % of people, 2025
- Health spending per person
- 3,922 US$ per person, 2023
- Doctors
- 2.83 per 1,000 people, 2022
Updated
Reviewed by Vidhi Upadhyay
Singapore Huntington's Disease Treatment Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Drug, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$2.4 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $1.5 Mn | — | — |
| 2025 (base) | $1.7 Mn | +$0.2 Mn | — |
| 2026 (forecast) | $1.9 Mn | +$0.2 Mn | +10.3% |
| 2027 (forecast) | $2.1 Mn | +$0.2 Mn | +21.7% |
| 2028 (forecast) | $2.3 Mn | +$0.2 Mn | +34.2% |
| 2029 (forecast) | $2.5 Mn | +$0.2 Mn | +48% |
| 2030 (forecast) | $2.8 Mn | +$0.3 Mn | +63.3% |
| 2031 (forecast) | $3.1 Mn | +$0.3 Mn | +80.1% |
| 2032 (forecast) | $3.4 Mn | +$0.3 Mn | +98.6% |
| 2033 (forecast) | $3.7 Mn | +$0.3 Mn | +119.1% |
| 2034 (forecast) | $4.1 Mn | +$0.4 Mn | +141.6% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $1.7 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $4.1 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 10.3% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Treatment, drug and end user (see all) |
| Key players | Teva Pharmaceutical, Neurocrine Biosciences, uniQure, PTC Therapeutics, Roche (see all) |
| Regulator in Singapore | HSASource: Health Sciences Authority. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Huntington's disease treatments manage movement and mood symptoms, while new gene-lowering drugs aim to slow this inherited brain disease.
Key segments of the huntington's Disease Treatment market include treatment (Symptomatic Drugs, Gene-Lowering Therapies and Supportive Care) and drug (Tetrabenazine, Deutetrabenazine and Valbenazine).
Better genetic diagnosis, orphan drug incentives, patient advocacy and new gene and enzyme therapies are driving the huntington's Disease Treatment market. More countries now have national rare disease plans.
Newborn genome screening, gene therapies and access programmes in emerging markets give the huntington's Disease Treatment market strong growth.
Very small patient numbers, long diagnosis delays, high treatment prices and limited specialist centres hold back the huntington's Disease Treatment market.
The huntington's Disease Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Therapeutic products need registration with the Health Sciences Authority (HSA).[1] MediShield Life gives basic health insurance to all citizens and permanent residents, alongside MediSave savings accounts.[2]
[1] Health Sciences Authority. Checked 14 Nov 2026.
[2] CPF Board, MediShield Life. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for huntington's Disease Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Singapore.
What doctors and scientists are doing in Huntington's Disease Treatment right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 20 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 19 Nov 2026.
From our blog
Singapore · 1 shared keyword
Singapore · 1 shared keyword
Singapore
Singapore
Singapore
Singapore
Medical Devices · Singapore
Healthcare Services · Singapore
Healthcare Services · Singapore
Digital Health · Singapore
Digital Health · Singapore
Medical Devices · Singapore